menu
    • menu

    Company profile for Stoke Therapeutics

    NEW Drugs in Dev: 4
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, liver, and kidney.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Stoke TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3 Preston Court, Suite 102 Bedford, MA 01730, USA
    Telephone
    Telephone
    781-430-8200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.stoketherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Stoke Therapeutics Names Clare Kahn PhD to Its Board of Directors
    Stoke Therapeutics Names Clare Kahn PhD to Its Board of Directors

    07 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-07/stoke-therapeutics-appoints-clare-kahn-phd-to-its-board-of-directors

    PHARMIWEB
    07 Apr 2026
    Share Share
    Stoke Aims To Restore Developmental Loss In Dravet Syndrome
    Stoke Aims To Restore Developmental Loss In Dravet Syndrome

    18 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/beyond-seizures-stokes-experimental-drug-aims-restore-developmental-loss-dravet-syndrome

    FIERCE BIOTECH
    18 Mar 2026
    Share Share
    Stoke Therapeutics Awards Inducements Under Nasdaq Rules
    Stoke Therapeutics Awards Inducements Under Nasdaq Rules

    17 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260317412877/en/Stoke-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635C4

    BUSSINESSWIRE
    17 Mar 2026
    Share Share
    Stoke Therapeutics Presents At TD Cowen Health Care Conference
    Stoke Therapeutics Presents At TD Cowen Health Care Conference

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224160878/en/Stoke-Therapeutics-to-Present-at-the-TD-Cowen-46th-Annual-Health-Care-Conference

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    Stoke Therapeutics Grants Inducements Under Nasdaq Rule 5635(c)
    Stoke Therapeutics Grants Inducements Under Nasdaq Rule 5635(c)

    18 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260218638927/en/Stoke-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635C4

    BUSINESSWIRE
    18 Feb 2026
    Share Share
    Stoke Therapeutics Doses First Patient in STK-002 Trial
    Stoke Therapeutics Doses First Patient in STK-002 Trial

    11 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-11/stoke-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-stk-002-a-potential-disease-mo

    PHARMIWEB
    11 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search